Table 2

Impacts of influenza virus type on clinical outcomes among HCT recipients, by multivariable analyses

OutcomeVirus type
Influenza B*
2009 H1N1*
Influenza A (N = 103)Influenza B (N = 40)2009 H1N1 (N = 18)Adjusted OR or HR (95% CI)PAdjusted OR or HR (95% CI)P
LRD 22 (21.4) 10 (25.0) 10 (55.6) 0.70 (0.3-1.9) .49 6.48 (1.4-31) .02 
Hypoxemia 22 (21.4) 11 (27.5) 10 (55.6) 0.85 (0.3-2.1) .73 3.96 (1.1-15) .04 
Mechanical ventilation 8 (7.8) 4 (10.0) 5 (27.8) 0.39 (0.1-1.8) .24 2.59 (0.5-15) .29 
Time to death by day 42 11 (10.7) 6 (15.0) 3 (16.7) 0.95 (0.3-2.7) .92 0.93 (0.2-4.6) .93 
Time to influenza-associated death 8 (7.8) 4 (10.0) 3 (16.7) 0.86 (0.2-3.0) .82 1.15 (0.2-5.9) .87 
OutcomeVirus type
Influenza B*
2009 H1N1*
Influenza A (N = 103)Influenza B (N = 40)2009 H1N1 (N = 18)Adjusted OR or HR (95% CI)PAdjusted OR or HR (95% CI)P
LRD 22 (21.4) 10 (25.0) 10 (55.6) 0.70 (0.3-1.9) .49 6.48 (1.4-31) .02 
Hypoxemia 22 (21.4) 11 (27.5) 10 (55.6) 0.85 (0.3-2.1) .73 3.96 (1.1-15) .04 
Mechanical ventilation 8 (7.8) 4 (10.0) 5 (27.8) 0.39 (0.1-1.8) .24 2.59 (0.5-15) .29 
Time to death by day 42 11 (10.7) 6 (15.0) 3 (16.7) 0.95 (0.3-2.7) .92 0.93 (0.2-4.6) .93 
Time to influenza-associated death 8 (7.8) 4 (10.0) 3 (16.7) 0.86 (0.2-3.0) .82 1.15 (0.2-5.9) .87 

Data are no. (%) of patients, unless otherwise indicated. The year of influenza diagnosed was forced into the multivariable models for all endpoint analyses. Influenza virus type, lymphocyte count, and early antiviral therapy were included as variables in all analyses. Multivariable models also included stem cell source for LRD analysis, acute GVHD for hypoxemia analysis, and corticosteroid treatment for mechanical ventilation analysis.

*

Seasonal influenza A is the reference.

ORs are shown for risk for LRD, hypoxemia, and mechanical ventilation, and HRs are shown elsewhere.

or Create an Account

Close Modal
Close Modal